TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
This Quarter Return
+8.25%
1 Year Return
-56.28%
3 Year Return
-45.76%
5 Year Return
+44.93%
10 Year Return
–
AUM
$138M
AUM Growth
+$138M
(-18%)
Cap. Flow
-$33.5M
Cap. Flow
% of AUM
-24.21%
Top 10 Holdings %
Top 10 Hldgs %
60.42%
Holding
51
New
5
Increased
14
Reduced
10
Closed
15
Top Buys
| 1 |
Biogen
BIIB
|
$5.54M |
| 2 |
Neogen
NEOG
|
$3.81M |
| 3 |
Ascendis Pharma
ASND
|
$3.66M |
| 4 |
Viatris
VTRS
|
$3.62M |
| 5 |
InMode
INMD
|
$3.21M |
Top Sells
| 1 |
Perrigo
PRGO
|
$9.09M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$6.02M |
| 3 |
Cigna
CI
|
$5.55M |
| 4 |
Bioventus
BVS
|
$5.25M |
| 5 |
Lantheus
LNTH
|
$5.25M |
Sector Composition
| 1 | Healthcare | 96.89% |
| 2 | Consumer Staples | 1.96% |
| 3 | Technology | 1.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MDRX
1
DELISTED
Veradigm Inc. Common Stock
MDRX
| $12.6M | 6.49% |
715,000
+30,000
| +4% | +$529K |
|
|
2
Viatris
VTRS
$12.3B
| $10.9M | 5.59% |
975,000
+325,000
| +50% | +$3.62M |
|
3
Phreesia
PHR
$1.88B
| $9.22M | 4.75% |
285,000
+25,000
| +10% | +$809K |
|
4
Cerus
CERS
$251M
| $9.13M | 4.7% |
2,500,000
+75,000
| +3% | +$274K |
|
5
Collegium Pharmaceutical
COLL
$1.22B
| $8.98M | 4.62% |
387,000
+87,000
| +29% | +$2.02M |
|
|
STRM
6
DELISTED
Streamline Health Solutions
STRM
| $7.79M | 4.01% |
4,930,882
| – | – |
|
7
Alkermes
ALKS
$4.78B
| $7.19M | 3.7% |
275,000
+75,000
| +38% | +$1.96M |
|
8
AngioDynamics
ANGO
$417M
| $6.75M | 3.47% |
490,000
+165,000
| +51% | +$2.27M |
|
|
9
Biogen
BIIB
$19.4B
| $5.54M | 2.85% |
+20,000
| New | +$5.54M |
|
|
10
Ascendis Pharma
ASND
$11.8B
| $5.5M | 2.83% |
45,000
+30,000
| +200% | +$3.66M |
|
|
11
Lantheus
LNTH
$3.73B
| $5.35M | 2.76% |
105,000
-103,000
| -50% | -$5.25M |
|
12
Tenet Healthcare
THC
$16.3B
| $4.64M | 2.39% |
95,000
-80,000
| -46% | -$3.9M |
|
13
SI-BONE Inc
SIBN
$719M
| $4.49M | 2.31% |
330,000
-130,000
| -28% | -$1.77M |
|
14
Pacira BioSciences
PCRX
$1.2B
| $3.86M | 1.99% |
100,000
-95,000
| -49% | -$3.67M |
|
|
15
Neogen
NEOG
$1.25B
| $3.81M | 1.96% |
+250,000
| New | +$3.81M |
|
16
Rigel Pharmaceuticals
RIGL
$697M
| $3.45M | 1.78% |
2,300,000
+300,000
| +15% | +$450K |
|
|
17
InMode
INMD
$944M
| $3.21M | 1.65% |
+90,000
| New | +$3.21M |
|
18
Tactile Systems Technology
TCMD
$297M
| $2.93M | 1.51% |
255,000
+30,000
| +13% | +$344K |
|
19
Merck
MRK
$210B
| $2.77M | 1.43% |
25,000
| – | – |
|
20
Turning Point Brands
TPB
$1.79B
| $2.7M | 1.39% |
125,000
-40,000
| -24% | -$865K |
|
21
DocGo
DCGO
$153M
| $2.65M | 1.37% |
375,000
| – | – |
|
22
Sanofi
SNY
$121B
| $2.42M | 1.25% |
50,000
-105,000
| -68% | -$5.09M |
|
23
AtriCure
ATRC
$1.84B
| $2.22M | 1.14% |
50,000
-17,500
| -26% | -$777K |
|
24
Ironwood Pharmaceuticals
IRWD
$214M
| $2.17M | 1.12% |
+175,000
| New | +$2.17M |
|
25
Fennec Pharmaceuticals
FENC
$247M
| $2.04M | 1.05% |
213,000
+38,000
| +22% | +$365K |
|